3 Asian Stocks Estimated To Be Trading At Up To 37.5% Below Intrinsic Value
As geopolitical tensions and energy price volatility continue to influence global markets, Asian equities have not been immune to these pressures. Despite these challenges, opportunities may exist for investors seeking undervalued stocks that are trading below their intrinsic value. In such a climate, identifying stocks with strong fundamentals and potential for growth can be key to navigating uncertain market conditions.
Here’s a peek at a few of the choices from the screener.
Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on the discovery, development, production, and commercialization of biological drugs for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$72.41 billion.
Operations: RemeGen’s revenue primarily comes from its biopharmaceutical research, service, production, and sales segment, generating approximately CN¥3.25 billion.
Estimated Discount To Fair Value: 24.4%
RemeGen’s stock is trading at HK$98.85, significantly below its estimated future cash flow value of HK$130.7, making it highly undervalued based on discounted cash flow analysis. The company’s earnings are forecast to grow at 24.91% annually, surpassing the Hong Kong market average of 12.4%. Recent approval of Disitamab Vedotin for a new indication and strategic licensing agreements further bolster its growth prospects despite recent insider selling concerns and high non-cash earnings levels.
SEHK:9995 Discounted Cash Flow as at Mar 2026
Overview: Eastroc Beverage (Group) Co., Ltd. manufactures and distributes beverages in China, Vietnam, and Malaysia, with a market cap of CN¥127.06 billion.
Operations: The company generates revenue of CN¥20.12 billion from the production, sales, and wholesale of beverages and pre-packaged foods across its operating regions.
Estimated Discount To Fair Value: 37.5%
Eastroc Beverage (Group) is trading at CN¥227.99, well below its estimated future cash flow value of CN¥364.81, highlighting its undervaluation based on discounted cash flow analysis. Earnings are projected to grow significantly at 21.83% annually over the next three years, although slightly slower than the overall Chinese market’s growth rate of 27.1%. Recent equity offerings totaling HKD 10.14 billion may enhance capital structure but could affect dividend stability due to an unstable track record.
SHSE:605499 Discounted Cash Flow as at Mar 2026
Overview: Accelink Technologies Co., Ltd. is engaged in the research, development, manufacturing, sales, and provision of technical services for optoelectronic chips, devices, modules, and subsystem products primarily in China with a market cap of CN¥71.07 billion.
Operations: The company’s revenue primarily comes from its Communication Equipment Manufacturing segment, which generated CN¥11.38 billion.
Estimated Discount To Fair Value: 28.1%
Accelink Technologies CoLtd is trading at CN¥88.1, significantly below its estimated future cash flow value of CN¥122.47, indicating undervaluation. The company’s earnings are forecast to grow robustly at 32% annually over the next three years, outpacing the Chinese market’s growth rate of 27.1%. Despite a volatile share price recently and a projected low return on equity (14.7%), its revenue is expected to increase by 20.5% per year, exceeding market expectations.
SZSE:002281 Discounted Cash Flow as at Mar 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:9995 SHSE:605499 and SZSE:002281.
This article was originally published by Simply Wall St.
